TMO logo

Thermo Fisher Scientific Inc. Stock Price

NYSE:TMO Community·US$169.5b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 226 Fair Values set on narratives written by author

TMO Share Price Performance

US$0
-402.13 (-100.00%)
US$611.56
Fair Value
US$0
-402.13 (-100.00%)
Price US$0

TMO Community Narratives

·
Fair Value US$611.56 20.3% undervalued intrinsic discount

Life Science Leadership And Pharma Partnerships Will Drive Long-Term Market Momentum

0users have liked this narrative
0users have commented on this narrative
80users have followed this narrative
·
Fair Value US$520 6.3% undervalued intrinsic discount

US China Tensions And Trade Restrictions Will Impair Margins

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$738.42 34.0% undervalued intrinsic discount

Aging Populations And Gene Therapies Will Drive Precision Medicine

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
US$540.27
9.8% undervalued intrinsic discount
Fair Value
Revenue
7% p.a.
Profit Margin
16%
Future PE
28x
Price in 2030
US$757.34
US$520
6.3% undervalued intrinsic discount
Revenue
5.8% p.a.
Profit Margin
15.66%
Future PE
28x
Price in 2029
US$659.24

Trending Discussion

Updated Narratives

TMO logo

The demand for personalized medicine will keep Thermo Fisher Scientific thriving

Fair Value: US$540.27 9.8% undervalued intrinsic discount
24 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TMO logo

TMO: High Conviction Tools Demand And New Platforms Will Drive Performance

Fair Value: US$611.56 20.3% undervalued intrinsic discount
80 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TMO logo

TMO: Revised Profitability And Tools Headwinds Will Shape Returns Through 2026

Fair Value: US$520 6.3% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Good value with acceptable track record.

1 Risk
4 Rewards

Thermo Fisher Scientific Inc. Key Details

US$45.2b

Revenue

US$26.7b

Cost of Revenue

US$18.5b

Gross Profit

US$11.7b

Other Expenses

US$6.8b

Earnings

Last Reported Earnings
Mar 28, 2026
Next Reporting Earnings
n/a
18.43
40.93%
15.15%
82.5%
View Full Analysis

About TMO

Founded
1956
Employees
125000
CEO
Marc Casper
WebsiteView website
www.thermofisher.com

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Recent TMO News & Updates

Narrative Update May 26

TMO: High Conviction Tools Demand And New Platforms Will Drive Performance

Thermo Fisher Scientific's analyst fair value estimate is updated from $648.28 to $611.56 as analysts weigh modestly different assumptions for discount rate, revenue growth, profit margins and future P/E, alongside mixed research commentary that includes fresh additions to high conviction lists and several price target cuts across the Street. Analyst Commentary Recent research on Thermo Fisher shows a mix of optimism and caution, with fresh inclusion in a high conviction list on one side and several price target cuts and neutral ratings on the other.

Recent updates

No updates